Table 3.
The ΔCt comparative method analysis for GSCs.
| Gene versus gene | Mean ΔCt | StdDev | Mean StdDev | Gene versus Gene | Mean ΔCt | StdDev | Mean StdDev |
|---|---|---|---|---|---|---|---|
| TBP versus SDHA | 3,73 | 0,84 | 1.05 | ALAS1 versus TBP | 0,56 | 1,51 | 1.27 |
| TBP versus HPRT1 | 1,85 | 0,86 | ALAS1 versus SDHA | −3,18 | 1,02 | ||
| TBP versus GAPDH | 8,48 | 0,92 | ALAS1 versus HPRT1 | −1,30 | 1,87 | ||
| TBP versus RPS18 | 8,99 | 1,00 | ALAS1 versus GAPDH | −7,93 | 1,27 | ||
| TBP versus ALAS1 | 0,56 | 1,51 | ALAS1 versus RPS18 | −8,43 | 1,37 | ||
| TBP versus ACTB | 8,67 | 0,85 | ALAS1 versus ACTB | 8,12 | 1,20 | ||
| TBP versus B2M | 9,29 | 0,88 | ALAS1 versus B2M | 8,73 | 0,99 | ||
| TBP versus UBC | −1,68 | 0,64 | ALAS1 versus UBC | −2,24 | 1,36 | ||
| TBP versus RPII | 0,99 | 1,99 | ALAS1 versus RPII | 0,43 | 0,85 | ||
|
| |||||||
| SDHA versus TBP | 3,73 | 0,84 | 0.97 | ACTB versus TBP | 8,67 | 0,85 | 0.98 |
| SDHA versus HPRT1 | −1,88 | 1,36 | ACTB versus SDHA | 4,94 | 0,63 | ||
| SDHA versus GAPDH | 4,75 | 0,75 | ACTB versus HPRT1 | 6,82 | 1,01 | ||
| SDHA versus RPS18 | 5,25 | 1,00 | ACTB versus GAPDH | 0,19 | 0,93 | ||
| SDHA versus ALAS1 | −3,18 | 1,02 | ACTB versus RPS18 | −0,31 | 1,18 | ||
| SDHA versus ACTB | 4,94 | 0,63 | ACTB versus ALAS1 | 8,12 | 1,20 | ||
| SDHA versus B2M | 5,56 | 0,90 | ACTB versus B2M | 0,62 | 0,83 | ||
| SDHA versus UBC | −5,41 | 0,89 | ACTB versus UBC | −10,35 | 0,67 | ||
| SDHA versus RPII | −2,75 | 1,33 | ACTB versus RPII | −7,69 | 1,54 | ||
|
| |||||||
| HPRT1 versus TBP | 1,85 | 0,86 | 1.37 | B2M versus TBP | 9,29 | 0,88 | 0.98 |
| HPRT1 versus SDHA | −1,88 | 1,36 | B2M versus SDHA | 5,56 | 0,90 | ||
| HPRT1 versus GAPDH | 6,63 | 1,42 | B2M versus HPRT1 | 7,44 | 1,27 | ||
| HPRT1 versus RPS18 | 7,13 | 1,23 | B2M versus GAPDH | 0,81 | 0,72 | ||
| HPRT1 versus ALAS1 | −1,30 | 1,87 | B2M versus RPS18 | 0,30 | 1,09 | ||
| HPRT1 versus ACTB | 6,82 | 1,01 | B2M versus ALAS1 | 8,73 | 0,99 | ||
| HPRT1 versus B2M | 7,44 | 1,27 | B2M versus ACTB | 0,62 | 0,83 | ||
| HPRT1 versus UBC | −3,53 | 1,03 | B2M versus UBC | −10,97 | 0,70 | ||
| HPRT1 versus RPII | −0,87 | 2,41 | B2M versus RPII | −8,30 | 1,47 | ||
|
| |||||||
| GAPDH versus TBP | 8,48 | 0,92 | 1.06 | UBC versus TBP | −1,68 | 0,64 | 1.02 |
| GAPDH versus SDHA | 4,75 | 0,75 | UBC versus SDHA | −5,41 | 0,89 | ||
| GAPDH versus HPRT1 | 6,63 | 1,42 | UBC versus HPRT1 | −3,53 | 1,03 | ||
| GAPDH versus RSP18 | 0,50 | 1,16 | UBC versus GAPDH | −10,16 | 0,86 | ||
| GAPDH versus ALAS1 | −7,93 | 1,27 | UBC versus RPS18 | −10,66 | 1,39 | ||
| GAPDH versus ACTB | 0,19 | 0,93 | UBC versus ALAS1 | −2,24 | 1,36 | ||
| GAPDH versus B2M | 0,81 | 0,72 | UBC versus ACTB | −10,35 | 0,67 | ||
| GAPDH versus UBC | −10,16 | 0,86 | UBC versus B2M | −10,97 | 0,70 | ||
| GAPDH versus RPII | −7,50 | 1,54 | UBC versus RPII | 2,67 | 1,68 | ||
|
| |||||||
| RPS18 versus TBP | 8,99 | 1,00 | 1.27 | RPII versus TBP | 0,99 | 1,99 | 1.64 |
| RPS18 versus SDHA | 5,25 | 1,00 | RPII versus SDHA | −2,75 | 1,33 | ||
| RPS18 versus HPRT1 | 7,13 | 1,23 | RPII versus HPRT1 | −0,87 | 2,41 | ||
| RPS18 versus GAPDH | 0,50 | 1,16 | RPII versus GAPDH | −7,50 | 1,54 | ||
| RPS18 versus ALAS1 | −8,43 | 1,37 | RPII versus RPS18 | −8,00 | 2,00 | ||
| RPS18 versus ACTIN | −0,31 | 1,18 | RPII versus ALAS1 | 0,43 | 0,85 | ||
| RPS18 versus B2M | 0,30 | 1,09 | RPII versus ACTB | −7,69 | 1,54 | ||
| RPS18 versus UBC | −10,66 | 1,39 | RPII versus B2M | −8,30 | 1,47 | ||
| RPS18 versus RPII | −8,00 | 2,00 | RPII versus UBC | 2,67 | 1,68 | ||